Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Genome editing tools in T cell-based immunotherapies

Chiara Bonini • 1 Apr 2022
ICLE 2022
Acute Myeloid Leukemia Leukemia

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes her presentation on multiple genome editing in T cells for cancer immunotherapy at the International Conference on Lymphocyte Engineering (ICLE) 2022. With advances in gene vector technology that have optimized the transfer and disruption of genes in T cells, ongoing research is focused around finding optimal combinations of tailored therapies. Dr Bonini describes the application of genome editing strategies for the potential treatment of acute myeloid leukemia (AML) and comments on the expansion of this approach into other indications. This interview took place at ICLE 2022.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Chiara Bonini

Enhancing personalized therapeutic cancer vaccine development
1:25
Enhancing personalized therapeutic cancer vaccine development
Chiara Bonini • 1 Apr 2022
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
1:57
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
Chiara Bonini • 1 Apr 2022
Cell therapy - progress to date and next steps
2:45
Cell therapy - progress to date and next steps
Chiara Bonini • 4 Apr 2016
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini • 4 Apr 2016

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals